Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
about
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesThe challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndromeThe effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever.Neonatal treatment of CINCA syndrome.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesAn expanding role for interleukin-1 blockade from gout to cancer.Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean feverTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases.The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activityBiological treatments: new weapons in the management of monogenic autoinflammatory disordersMonogenic autoinflammatory diseases: concept and clinical manifestations.Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Interleukin-1 as a mediator of fatigue in disease: a narrative review.Treating inflammation by blocking interleukin-1 in humans.Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus.Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activityCanakinumab in pediatric rheumatic diseases.Anakinra for cryopyrin-associated periodic syndrome.Monogenic autoinflammatory diseases.Pathogenesis of systemic inflammatory diseases in childhood: "Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome".Recommendations for the management of autoinflammatory diseases.Impact of IL-1 inhibition on fatigue associated with autoinflammatory syndromes.Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain.Pharmacological treatment options for cryopyrin-associated periodic syndromes.A Comprehensive Overview of the Hereditary Periodic Fever Syndromes.Anti-inflammatory response following uptake of apoptotic bodies by meningothelial cells.Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study.High mobility group box 1 skews macrophage polarization and negatively influences phagocytosis of apoptotic cells.Muckle-Wells syndrome: clinical perspectives.Neurology of the cryopyrin-associated periodic fever syndrome.[Evidence of treatment of chronic inflammation in childhood and adolescence with biologics].Early progression of atherosclerosis in children with chronic infantile neurological cutaneous and articular syndrome.Challenges in diagnosing Muckle-Wells syndrome: identifying two distinct phenotypes.[Cryopyrin-associated periodic syndrome].Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.
P2860
Q26799747-C2A0A0B3-CC82-429F-B29F-C1D814B999D5Q28070297-8138D5FF-D9F3-4F7A-830D-F96B4E6D4039Q34039381-EEE8251C-B7B4-4F33-845B-ABA0CBE29D38Q34908472-CF1BE9FF-B3F6-4FD4-9F1E-571DFFEC74BDQ35133812-04FEE27D-8CF1-4043-BF46-073F0D34F577Q35219001-F7471854-A2A8-4BA9-91C9-F911309212F9Q36027314-C3194284-5BCF-4E7A-A3A6-90944FD79A9CQ36816872-CB71638F-6A89-4A9D-8520-950907D364DDQ36903288-DAF4C919-5038-4E5E-85A7-1311D0C76CC7Q36903351-DF46CD98-18D3-49BC-8C63-012DFB3041CFQ37077564-253E8FB8-7DB5-4F58-A87B-B2666CB85CCAQ37162157-3A5AAEBB-48BF-4FD8-9F35-DE19CE56D0EFQ37331996-E55DE7CD-A537-4B90-8DAC-F34742FC1D4DQ37485709-50E025B7-9125-4471-BC41-5BC6B4728F5DQ37597282-7DE59E9F-F7E2-4C91-AAF6-55D7E3069119Q37636664-2A63A304-9632-4DFD-AA9E-E43E08C35C4EQ37690679-14BB5031-E229-4778-9C6F-388CD7F1D5A3Q37690725-7D58C7A9-3541-40D5-BD39-C8030D6DDC0DQ38085662-ABEF7D30-1DAB-4850-AB4E-F202A49B5F23Q38168948-83F66F2F-DC4A-42B9-A485-0A66DDC77E1DQ38211947-D4C19EC9-85BA-4F8C-8612-A30139EB647CQ38212949-27823131-3513-4B72-9910-7D09878FC7EBQ38537504-80857E46-78EC-450D-ABC0-F842495978DCQ38542409-61A00B04-45FD-476A-BFF6-618F7BE2FEDAQ38574807-7233694E-2001-4CBB-A03A-BB09F56CC1F9Q38646694-B6A0A10A-9ADB-4C0D-923E-8F4B4E11A797Q38674213-FD696902-D9D4-4C7F-8269-7B30287E4F48Q38805718-0574F903-FC06-412C-ACFC-5678457D5860Q39021326-3DCE354E-AEEA-4EA7-AAA3-9F25A9E8342BQ39084627-DB924CC1-BF10-4751-A0B8-53761F77F931Q39301708-9FAC5C36-0E99-4436-87E8-762C9D631A49Q39382198-2DA07D02-78D3-4F1B-AD7E-AF215199DA4AQ39385492-A8C5292D-22F3-4AA6-B9FA-E780C553A04FQ39458288-C6B8F9C0-0513-4681-A199-3490C241C625Q40115834-8391BC6F-8E8C-4010-82C5-7F16397D26C2Q40179129-B5180554-D456-4CF7-89EC-7F366061E1DBQ40207414-4649168A-E920-45E8-96B7-6DCE60C73FB8Q40231494-6CD7FB5F-AC5E-497C-96D4-DCBFE0A2E89CQ40289375-7309732A-6793-4DA5-89A2-F3B4BFBD17BAQ45325652-5B9A0116-33EB-4977-9FF1-1A369CA2D2BD
P2860
Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Sustained remission of symptom ...... ed randomized withdrawal study
@ast
Sustained remission of symptom ...... ed randomized withdrawal study
@en
type
label
Sustained remission of symptom ...... ed randomized withdrawal study
@ast
Sustained remission of symptom ...... ed randomized withdrawal study
@en
prefLabel
Sustained remission of symptom ...... ed randomized withdrawal study
@ast
Sustained remission of symptom ...... ed randomized withdrawal study
@en
P2093
P2860
P50
P356
P1476
Sustained remission of symptom ...... ed randomized withdrawal study
@en
P2093
Alberto Ferreira
Canakinumab in CAPS Study Group
Jasmin B Kuemmerle-Deschner
Karine Lheritier
Kieron S Leslie
Neha Patel
Philip N Hawkins
Ralph Preiss
Richard Mouy
P2860
P2888
P356
10.1186/AR3535
P577
2011-12-09T00:00:00Z
P5875
P6179
1020070762